Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2008
08/26/2008US7417048 Aryl-substituted derivatives of cycloalkyl and branched chain alkyl carboxylic acids useful as antinociceptive drugs for peripheral targets
08/26/2008US7417047 Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation
08/26/2008US7417046 Inhibiting the proteolytic activity of cathepsin S; 1-[4-(5-Chloro-1H-indol-3-yl)-piperazine-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol; antiarthritic agent; autoimmune disease: lupus, rheumatoid arthritis, and asthma
08/26/2008US7417045 Antiinflammatory agents;to treat chemokine mediated diseases; Antitumor agents; autoimmune diseases
08/26/2008US7417044 Tadalafil having a large particle size and a process for preparation thereof
08/26/2008US7417043 3-substituted 4-(phenyl-N-alkyl)-piperazine derivatives; central nervous system disorders; dualistic dopaminergic action profile with antagonist-like effects on brain neurochemistry and mild agonist-like effects on normal behavior, induce inhibition of behavior in hyperactivity; oral bioavailability
08/26/2008US7417042 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents
08/26/2008US7417041 Imidazopyrimidines as transforming growth factor (TGF) inhibitors
08/26/2008US7417040 hormone sensitive diseases such as prostate hypertrophia, benign prostatic hyperplasia, adenomas and neoplasies of the prostate, prostate cancer, hirsutism, and polycystic ovary syndrome; dibenz[b,f]azocine, dibenzo[b,f][1,4]thiazocine, dibenz[b,f][1,5]oxazocine derivatives; anticancer, antitumor agents
08/26/2008US7417039 Use of substituted azetidinone compounds for the treatment of sitosterolemia
08/26/2008US7417038 administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity; a beta receptor blocker or a compound which inhibits the effect of aldosterone
08/26/2008US7417037 Ulcerative colitis and Crohn's disease; 5-aminosalicylic acid or 4-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine)
08/26/2008US7417036 adding organic solvent and dissolivng adefovir dipivoxil ultrasonically to form solution, and spray drying; have different melting points, solubility, and density
08/26/2008US7417035 Phospholipid derivatives of non-steroidal anti-inflammatory drugs
08/26/2008US7417034 Pharmaceutically active uridine esters
08/26/2008US7417033 Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells
08/26/2008US7417032 D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture
08/26/2008US7417031 Induction apoptosis; oxidation resistance; preservatives
08/26/2008US7417030 Thrombolytic agents, restenosis, hypotension agents, heart failure, antiarrhythmia and -inflammation agents, angina, stroke, atherosclerosis, antiischemic agents, angiogenesis related disorders, anti carcinogenic and -tumor agents
08/26/2008US7417026 Mobilization of hematopoietic cells
08/26/2008US7417024 template-fixed beta -hairpin peptidomimetics incorporating a template-fixed chain of 7 or 11 alpha -amino acid residues which, depending on their position in the chain, are Gly, or Pro, or of certain types; inhibitors of various serine proteases such as trypsin, human cathepsin G, and thrombin
08/26/2008US7417023 Targeted delivery of bioaffecting compounds for the treatment of cancer
08/26/2008US7417022 Amino acid for deliverying active materials; bioavailability
08/26/2008US7417013 Warming and nonirritating lubricant compositions and method of comparing irritation
08/26/2008US7416887 Preparing viable stem cells in culture; prepare nutrient broth containing ligand and preferential receptor, inoculate with cells, monitor propagation and viability of cells
08/26/2008US7416868 polypeptide comprising an amino acid sequence having polyene polyketide synthase activity; involved in the biosynthesis of novel polyketides, inhibitors of fungal cell growth and cancer cell growth
08/26/2008US7416864 Method for treating dyskinesia
08/26/2008US7416853 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
08/26/2008US7416848 DNA encoding SNORF25 receptor
08/26/2008US7416749 Including unique combination of fruits, vegetables, herbs, and optionally vitamins, minerals, and specialty ingredients such as bioflavonoids, lycopene, lutein, for decreasing free radical damage
08/26/2008US7416748 Arthritis phyto-nutraceutical synergistic composition
08/26/2008US7416744 Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use
08/26/2008US7416741 Administering a mono-, di- , tri-, or, preferably, tetrathiomolybdate that binds/complexes endogenous copper to form an irreversible tripartite agent-copper-protein complex; chelation; side effect reduction; pulmonary, cystic, pancreatic, myocardial, gastrointestinal fibrosis, acute respiratory distress
08/26/2008US7416740 Animal feed adjuvant
08/26/2008US7416738 Pharmaceutical pills comprising drugs such as non-steroidal antiinflammatory agents, and cores surrounded by shells, having apertures for timed or sustained drug delivery
08/26/2008US7416736 combining 3-benzo[b]thiene-2-yl-5,6-dihydro-1,4,2-oxathiazine-4-oxide and one or more compositions; synergistic effect of these compounds
08/26/2008US7416730 Derivatives of the IL-2 receptor gamma chain, their production and use
08/26/2008US7416724 Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
08/26/2008US7416723 Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
08/26/2008US7416720 Topical aqueous composition as nail hardener to decrease brittleness and increase strength
08/26/2008US7416306 Laser projector
08/26/2008CA2496495C An improved process for the preparation of xanthophyll crystals
08/26/2008CA2490299C Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof
08/26/2008CA2432129C Pyrazole compounds useful as protein kinase inhibitors
08/26/2008CA2429117C Remedy for diabetes mellitus
08/26/2008CA2410446C Esmolol formulation
08/26/2008CA2397961C Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
08/26/2008CA2392165C Vitamin d analogues
08/26/2008CA2387920C A new use of levosimendan
08/26/2008CA2378487C Antibiotic(s)-polymer combination
08/26/2008CA2361614C Compositions for treating inflammatory response
08/26/2008CA2360300C A transdermal composition of an antivomiting agent and a preparation containing the same
08/26/2008CA2347474C Bicyclic nitrogen heterocycles
08/26/2008CA2347110C A method for preventing, reducing, and treating radiation cystitis using hyaluronic acid
08/26/2008CA2343880C Polyketide synthase enzymes and recombinant dna constructs therefor
08/26/2008CA2333669C 17.beta.-amino and hydroxylamino-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
08/26/2008CA2330681C Control of pain with endogenous cannabinoids
08/26/2008CA2323810C Ophthalmic solution comprising glycogen
08/26/2008CA2312021C Use of ketolides for preparing arterial thrombotic complications related to atherosclerosis
08/26/2008CA2292638C Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps
08/26/2008CA2289761C Method of making microencapsulated dna for vaccination and gene therapy
08/26/2008CA2284909C Medical food for diabetics
08/26/2008CA2274825C Substituted nitrogen containing heterocycles as inhibitors of p38 protein kinase
08/26/2008CA2274773C Aqueous therapeutic agents of ibuprofen
08/26/2008CA2239780C A process for regulating vagal tone
08/26/2008CA2235225C Nima interacting proteins
08/26/2008CA2208981C Novel trienoic retinoid compounds and methods
08/26/2008CA2171550C Nucleosides with anti-hepatitis b virus activity
08/26/2008CA2160779C Method and composition for topical treatment of damaged tissue using histamine phosphate as active ingredient
08/26/2008CA2152401C Synergising association having an antagonist effect on nk1 and nk2 receptors
08/22/2008CA2617688A1 Solid dosage formulations containing weight-loss drugs
08/22/2008CA2579382A1 Controlled release delivery device
08/21/2008WO2008101247A2 6 ' substituted indole and indazole derivatives having 5-ht6 receptor affinity
08/21/2008WO2008101240A1 Compounds having a cyclic moiety and compositions for delivering active agents
08/21/2008WO2008101239A1 Compositions and methods for alleviating skin disorders
08/21/2008WO2008101238A2 Natural products from vinca
08/21/2008WO2008101214A2 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
08/21/2008WO2008101202A1 N-17-alkylated prodrugs of opioids
08/21/2008WO2008101195A2 Drug resistance reversal in neoplastic disease
08/21/2008WO2008101141A2 Cancer treatment method
08/21/2008WO2008101139A1 Sustained-release tablet formulations of piperazine-piperidine antagonists and agonists of the 5-ht1a receptor having enhanced intestinal dissolution
08/21/2008WO2008101076A1 Improved stability in vitamin and mineral supplements
08/21/2008WO2008101064A1 Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist
08/21/2008WO2008101052A2 Compositions and methods for treating, reducing, ameliorating, or preventing infections of the ear or upper respiratory tract
08/21/2008WO2008101029A2 Use of thiazole, oxazole and imidazole compounds for the treatment of sodium channel-mediated diseases or conditions
08/21/2008WO2008101012A1 Use of ranolazine for the treatment of non-coronary microvascular diseases
08/21/2008WO2008101008A1 Use of ranolazine for the treatment of coronary microvascular diseases
08/21/2008WO2008101002A1 Use of ranolazine for the treatment of cardiovascular diseases
08/21/2008WO2008100997A2 Methods for treating or preventing hemorrhagic cystitis using a glycerophosphate salt
08/21/2008WO2008100992A1 Intravenous solutions comprising ranolazine
08/21/2008WO2008100985A2 Combination of lbh589 with other therapeutic agents for treating cancer
08/21/2008WO2008100980A1 Methods for treating or preventing inflammation using a glycerophosphate salt
08/21/2008WO2008100977A2 Carbamates therapeutic release agents as amidase inhibitors
08/21/2008WO2008100969A1 Bifunctional active sites for adsorption of nox
08/21/2008WO2008100933A2 Reducing side effects of tramadol
08/21/2008WO2008100926A1 Treatment of comorbid premature ejaculation and erectile dysfunction
08/21/2008WO2008100913A2 Early detection and prognosis of colon cancers
08/21/2008WO2008100912A1 Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
08/21/2008WO2008100886A1 Preparation and use of deuterated udenafil analogues as highly selective pde5 modulators for the treatment of erectile dysfunction
08/21/2008WO2008100874A2 Pka buffered vitamin c composition and method